AVLN today
$31.17+$1.67 (+5.66%)close Nov 10, 2026Trend
DailyDowntrend (confirmed)
4 hourSymmetric Triangle
1 hourStrong Bullish
15 minStrong Bullish
5 minSymmetric Triangle
Daily trend turns up above $26.32
Key levels
Resistance$38.70
Resistance$34.22
Support$30.45
Support$28.52
Latest news & SEC filings
AnalystRaymond James starts Avalyn Pharma coverage with Outperform rating, $60 price target
ProductAvalyn Pharma says journal publishes AP02 Phase 1 findings
All AVLN news →Nasdaq · Healthcare
Avalyn Pharma Inc. (AVLN)
What Is the Price Target for AVLN?
SEPT Low Target
$49.73
SEPT Mid Target
$58.50
SEPT High Target
$67.27
Analyst Consensus
$58.50
Is AVLN a Buy or Sell Right Now?
Thesis
- •Smart money flows are positive — institutional and insider activity shows net buying.
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for AVLN.
Start Free Trial →Is AVLN Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
Analyst Consensus
Fair Value
$58.50
5
Moat Score
NONE
0/9
Piotroski Score
N/A
Altman Z-Score
What Is Smart Money Doing with AVLN?
Insider Signal
BUYING
4 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
HIGH
Signal: HIGH_SHORT_INTEREST
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →AVLN Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
N/A
FCF Growth YoY
N/A%
Revenue Trend
UNKNOWN
Dark Pool Trades for AVLN
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for AVLN, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 21:00:37 | $31.17 | 2,182 | $$68K | SELL |
| 20:38:22 | $31.08 | 1,100 | $$34K | MIDPOINT |
| 18:16:16 | $30.54 | 1,663 | $$51K | BUY |
| 15:06:45 | $30.39 | 1,998 | $$61K | SELL |
| 21:00:07 | $29.50 | 3,055 | $$90K | BUY |
5 dark pool trades shown · $$304K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for Avalyn Pharma Inc. (AVLN) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →AVLN — frequently asked questions
What is AVLN stock price today?
Avalyn Pharma Inc. (AVLN) is at $31.17, up 5.66% (+$1.67) at the Nov 10, 2026 close.
Why is AVLN stock moving today?
Latest AVLN news — Oct 2, 2026: Raymond James starts Avalyn Pharma coverage with Outperform rating, $60 price target · Sep 21, 2026: Avalyn Pharma says journal publishes AP02 Phase 1 findings
What is the AVLN price target?
The average analyst price target for AVLN is $58.50, ranging from $51 to $80, based on 4 analysts. Latest: Raymond James initiates on Oct 2, 2026.
What do analysts rate AVLN?
Analyst ratings for AVLN: 0 Buy, 5 Hold, 0 Sell — consensus Hold.
Did AVLN beat earnings?
AVLN last reported on Aug 12, 2026: EPS -$0.98 vs -$0.78 expected — a miss of 26.2%.
How much debt does AVLN have?
Avalyn Pharma Inc. reported $15M of debt and $264M of cash (Jun 30, 2026).
What are AVLN support and resistance levels?
Support: $30.45, $28.52, $24.82. Resistance: $34.22, $38.70.
What are insiders doing with AVLN?
Insider activity: BUYING, 4 buys and 0 sells in the last 90 days.
What is the latest news on AVLN?
Oct 2, 2026: Raymond James starts Avalyn Pharma coverage with Outperform rating, $60 price target · Sep 21, 2026: Avalyn Pharma says journal publishes AP02 Phase 1 findings